Why this matters
- Long-acting IV treatment represents an alternative treatment strategy for HIV-infected patients to achieve viral suppression.
- Findings show that patients prefer a long-acting regimen over prior oral therapy.
- 566 participants (283/group); median, 34 years.
- At week 48, 2.1% (6) of LA vs 2.5% (7) of CAR group had HIV-1 RNA ≥50 copies/mL.
- Adjusted difference: −0.4 (95% CI, −2.8 to 2.1) percentage points.
- At week 48, 93.6% (265) of LA vs 93.3% (264) of CAR group achieved HIV-1 RNA
- Adjusted difference: 0.4 (95% CI, −3.7 to 4.5) percentage points.
- Virologic failures occurred in 4 patients in the LA group and 3 in CAR.
- 3 in each group had resistance mutations.
- 86% of LA participants had >1 injection site reaction (82% cited pain); 4 withdrew.
- 61.31% LA vs 56.03% CAR reported high treatment satisfaction (HIV Treatment Satisfaction Questionnaire).
- Adjusted difference: 0.44 (95% CI, −0.48 to 1.37).
- Randomized, open-label, phase 3 noninferiority study comparing switch to LA IV cabotegravir plus rilpivirine monthly vs daily oral CAR in ART-naive HIV-positive adults.
- Funding: ViiV Healthcare, Janssen.
- Selection bias.
- Limited generalizability.